貝康醫療-B(02170.HK)香港公開發售獲402.8倍認購 上限定價27.36港元/股
格隆匯 2 月 5日丨貝康醫療-B(02170.HK)發佈公吿，公司全球發售6666.7萬股股份，其中香港發售股份3333.5萬股，國際發售股份3333.2萬股，另有15%超額配股權；發售價定於每股發售股份27.36港元，每手買賣單位500股；中信證券為獨家保薦人，預期股份將於2021年2月8日於聯交所主板掛牌上市。
國際發售項下初步提呈發售的發售股份已獲大幅超額認購，相當於國際發售項下初步可供認購H股總數的約21.8倍。香港公開發售項下初步提呈發售的香港發售股份獲大幅超額認購。合共接獲264,120份有效申請，以認購合共26.85億股香港發售股份，相當於香港公開發售項下初步可供認購的香港發售股份約402.8倍。
基於發售價每股發售股份27.36港元，根據基石投資協議，基石投資者已認購的發售股份數目現已釐定。OrbiMed Funds已認購566.75萬股；Lake Bleu Prime已認購566.75萬股；CRF已認購566.75萬股；AHAM已認購283.35萬股；WinTwin已認購283.35萬股；Foresight Funds已認購141.65萬股；及常春藤作為代表IvyRock Funds的全權投資經理或全權資產管理人已認購 141.65萬股，合共認購2550.25萬股發售股份，相當於緊隨全球發售完成後公司已發行股本的約9.6%；全球發售完成後已發行H股的約34.4%；及全球發售項下發售股份數目的約38.3%，各情況下均假設超額配股權未獲行使。
按發售價每股發售股份27.36港元計算，假設超額配股權未獲行使，公司自全球發售收取的所得款項淨額估計約為17.167億港元。公司擬將全球發售所得款項約30%分配予公司的核心產品PGT-A試劑盒；約20%將用於公司PGT-M試劑盒的臨牀試驗、註冊申報及商業化；約30%將分配用於公司其他產品的開發、臨牀試驗及註冊申報；約10%將用於提高公司的研發能力及提升公司的技術；及約10%將用作公司的營運資本及一般企業用途。倘超額配股權獲悉數行使，公司將就發行1000萬股額外H股收取額外所得款項淨額2.627億港元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
